| abstract |
The present invention provides a PPAR agonist, or a pharmaceutically acceptable salt thereof, alone or (i) an HDL increasing compound; (Ii) anti-diabetic drugs; (Iii) antihypertensive drugs; (Iv) a cholesterol absorption modulator; (V) apo-A1 analogs and mimetics; (Vi) a renin inhibitor; (Vii) a thrombin inhibitor; (Viii) an aldosterone inhibitor; (Ix) GLP-1 agonist; (X) a glucagon receptor antagonist; (Xi) cannabinoid receptor 1 antagonist; (Xii) an anti-obesity agent; and (xiii) an inhibitor of platelet aggregation or in each case in combination with at least one active ingredient selected from the group consisting of pharmaceutically acceptable salts thereof, and It relates to a pharmaceutical composition optionally comprising a pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention comprises addiction (eg, nicotine and cocaine), dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, blood vessel Disease, cardiovascular disease, stroke, intermittent claudication, post-PCTA restenosis, hypertension, obesity including reduced CV risk in diabetics, inflammation, arthritis, cancer including breast cancer, colon cancer and prostate cancer, Alzheimer's disease, skin disease , Respiratory disease, eye disease, IBD (irritable bowel disease), Crohn's disease, low fibrinolysis, hypercoagulable state, metabolic cardiovascular syndrome, high CRP, appearance of microalbumin content, decreased proteinuria, Renal failure (DM, non-DM), NASH (non-alcoholic steatohepatitis), non-alcoholic fatty liver, CV events in patients with high CRP, vascular dementia, Scabies, ischemia-reperfusion injury, asthma, COPD, eosinophilia, RA, airway hypersensitivity (AHR), inflammatory gastrointestinal diseases (eg ulcerative colitis), antigen-induced inflammatory response Can be used for treatment of disease. The compounds of the present invention are useful as hypoglycemic agents for the treatment and prevention of conditions such as impaired glucose tolerance, hyperglycemia, insulin resistance, type 1 and type 2 diabetes and syndrome X, particularly in mammals. . Also, administering the combination of the present invention for improving cardiac metabolism and protecting the heart in patients who have undergone heart transplantation, to promote smoking cessation or smoke saving, and to prevent and treat smoking-related conditions Is also considered. |